Prognostic factors in patients presenting with severe neurological forms of Wilson's disease

QJM: An International Journal of Medicine

Volumn 98, Issue 8, 2005, Pages 557-563

  Prashanth, L K ^a   Taly, A B ^a   Sinha, S ^a   Ravishankar, S ^a   Arunodaya, G R ^a   Vasudev, M K ^a   Swamy, H S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLAMINE; ZINC;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FATALITY; FEMALE; GENERAL CONDITION DETERIORATION; GENERAL CONDITION IMPROVEMENT; HEMATOLOGIC DISEASE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RETREATMENT; SCORING SYSTEM; SYMPTOM; WHITE MATTER; WILSON DISEASE;

EID: 26444506853     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci095     Document Type: Article

References (20)

1. Meenakashi-Sundaram S, Taly AB, Kamat V, Arunodaya GR, Rao S, Swamy HS. Autonomic dysfunction in Wilson's disease - A clinical and electron hysiological study. Clin Auton Res 2002; 12:185-9.
2. Chu NS. Sensory evoked potentials in Wilson's disease. Brain 1986; 109:491-501.
3. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third symposium on Parkinson's disease. Edinburgh, Livingstone, 1969; 152-7.
4. Wilson SAK. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34 295-507.
5. Cumings JN. The copper and iron content of brain and liver in the normal and in hepatolenticular degeneration. Brain 1948; 71:410-15.
6. Cumings JN. The effect of BAL on hepatolenticular degeneration. Brain 1951; 74:10-22.
7. Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med 2000; 223:39-46.
8. Walshe JM, Yealland M. Chelation treatment of neurological Wilson's disease. Q J Med 1993; 86:197-204.
9. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: Clinical presentation and use of prognostic index. Gut 1986; 27 1377-81.
10. Walshe JM, Dixon AK. Dangers of non-compliance in Wilson's disease. Lancet 1986; 12; 1:845-7.
11. The WHOQOL group. The World Health Organization quality of life assessment(WHOQOL): Posistion paper from the world health organization. Soc Sci Med 1995; 41:1403-9.
12. Hu J, Lu D, Wang G. Study on the clinical misdiagnosis of hepatolenticular degeneration. Zhonghua Yi Xue Za Zhi 2001; 81 642-4.
13. Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS. Wilson's disease: Diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry 2004; 75:907-9.
14. Scheinberg IH, Sternlieb I, eds. Wilson's disease. Philadelphia, WB Saunders, 1984.
15. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44:490-3.
16. Hoogenraad TU. Dangers of interrupting decoppering treatment in Wilson's disease. Arch Neurol 1994; 51:972-3.
17. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): Population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997; 61:317-28.
18. Maier-Dobersberger T, Ferenci P, Polli C, et al. Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med 1997; 127:21-6.
19. Wilson disease mutation database. Available at [www.medgen.med.ualberta.ca/database.html] Curators: Kenney S, Cox DW.
20. Stapelbroek JM, Bollen CW, van Amstel JK, et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: Results of a meta-analysis. J Hepatol 2004; 41 758-63.